Abstract:Enterococcus faecium is a frequent causative agent of nosocomial infection mainly acquired from outgoing hospital patients (Hospital Acquired Infection—HAIs). They are largely involved in the outbreaks of bacteremia, UTI, and endocarditis with a high transmissibility rate. The recent emergence of VRE strain (i.e. vancomycin resistant enterococcus) turned it into high priority pathogen for which new drug research is of dire need. Therefore, in current study, pangenome and resistome analyses were performed for available antibiotic-resistant genomes ( n = 216) of E. faecium . It resulted in the prediction of around 5,059 genes as an accessory gene, 1,076 genes as core and 1,558 genes made up a unique genome fraction. Core genes common to all strains were further used for the identification of potent drug targets by applying subtractive genomics approach. Moreover, the COG functional analysis showed that these genomes are highly enriched in metabolic pathways such as in translational, ribosomal, proteins, carbohydrates and nucleotide transport metabolism. Through subtractive genomics it was observed that 431 proteins were non-homologous to the human proteome, 166 identified as essential for pathogen survival while 26 as potential and unique therapeutic targets. Finally, 3-dehydroquinate dehydrogenase was proposed as a potent drug target for further therapeutic candidate identification. Moreover, the molecular docking and dynamic simulation technique were applied to performed a virtual screening of natural product libraries (i.e., TCM and Ayurvedic compounds) along with 3-amino-4,5-dihydroxy-cyclohex-1-enecarboxylate (DHS) as a standard compound to validate the study. Consequently, Argeloside I, Apigenin-7- O -gentiobioside (from Ayurvedic library), ZINC85571062, and ZINC85570908 (TCM library) compounds were identified as potential inhibitors of 3-dehydroquinate dehydrogenase. The study proposed new compounds as novel therapeutics, however, further experimental validation is needed as a follow-up. Communicated by Ramaswamy H. Sarma

A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria

Correction to "A Vancomycin-Templated DNA-Encoded Library for Combating Drug-Resistant Bacteria"

Enhancing the antibacterial efficacy of vancomycin analogues: targeting metallo-β-lactamases and cell wall biosynthesis

Vancomycin-Polyguanidino Dendrimer Conjugates Inhibit Growth of Antibiotic-Resistant Gram-Positive and Gram-Negative Bacteria and Eradicate Biofilm-Associated S. aureus

Design and Synthesis of Pyrophosphate-Targeting Vancomycin Derivatives for Combating Vancomycin-Resistant Enterococci.

Modification of Vancomycin Structure to Combat against Emerging Vancomycin Resistance

A Biochemical Lanthanide-Encoding Approach Enables Quantitative Monitoring of the Bacterial Response to Vancomycin Treatment.

Design and synthesis of broad-spectrum antimicrobial amphiphilic peptidomimetics to combat drug-resistance

Extra Sugar on Vancomycin: New Analogues for Combating Multidrug-Resistant Staphylococcus Aureus and Vancomycin-Resistant Enterococci.

Future challenges with DNA-encoded chemical libraries in the drug discovery domain.

Potentiation of Vancomycin: Creating Cooperative Membrane Lysis through a “Derivatization-for-Sensitization” Approach

Computer-aided drug design to generate a unique antibiotic family

Design, Synthesis and Biological Activity of Novel Demethylvancomycin Dimers Against Vancomycin-Resistant Enterococcus Faecalis

Combination of Vancomycin and Guanidinium-Functionalized Helical Polymers for Synergistic Antibacterial Activity and Biofilm Ablation

Screening Ultra-Large Encoded Compound Libraries Leads to Novel Protein-Ligand Interactions and High Selectivity

Selecting a DNA-Encoded Chemical Library Against Non-immobilized Proteins Using a “Ligate–cross-Link–purify” Strategy

Pangenome profiling of novel drug target against vancomycin-resistant Enterococcus faecium

Highly pure DNA-encoded chemical libraries by dual-linker solid-phase synthesis

Discovery and optimization of tetrahydroacridine derivatives as a novel class of antibiotics against multidrug-resistant Gram-positive pathogens by targeting type I signal peptidase and disrupting bacterial membrane

VFDB 2025: an integrated resource for exploring anti-virulence compounds

Functionality‐Independent DNA Encoding of Complex Natural Products